You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEstrone
Accession NumberDB00655  (APRD00588)
TypeSmall Molecule
GroupsApproved
DescriptionEstrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion of adrostenedione. Estrone may be further metabolized to 16-alpha-hydroxyestrone, which may be reduced to estriol by estradiol dehydrogenase.
Structure
Thumb
Synonyms
3-Hydroxy-1,3,5(10)-estratrien-17-one
Estrona
Estrone
Estronum
follicular hormone
Folliculin
Oestrone
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Estragyn Vaginal CreamCream0.1 %VaginalSearchlight Pharma Inc1987-12-31Not applicableCanada
Oestrilin Cones VaginauxSuppository.25 mgVaginalDesbergers LtÉe, Division Of Technilab Inc.1951-12-312004-08-09Canada
Oestrilin Creme Vaginale 1mgCream1 mgVaginalDesbergers LtÉe, Division Of Technilab Inc.1968-12-312004-08-23Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EstroneWatson
Brand mixturesNot Available
SaltsNot Available
Categories
UNII2DI9HA706A
CAS number53-16-7
WeightAverage: 270.3661
Monoisotopic: 270.161979948
Chemical FormulaC18H22O2
InChI KeyDNXHEGUUPJUMQT-CBZIJGRNSA-N
InChI
InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16,19H,2,4,6-9H2,1H3/t14-,15-,16+,18+/m1/s1
IUPAC Name
(1S,10R,11S,15S)-5-hydroxy-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-2(7),3,5-trien-14-one
SMILES
[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
Pharmacology
IndicationFor management of perimenopausal and postmenopausal symptoms.
Structured Indications
PharmacodynamicsEstrone, a synthetically prepared or naturally occurring steroidal estrogen obtained from pregnant equine urine, is the primary circulating estrogen after menopause. Estrone is naturally derived from the peripheral conversion of androstenedione by an aromatase enzyme found in adipose tissues and is converted to estradiol in peripheral tissues. The estrogenic potency of estrone is one third that of estradiol. Estropipate is piperazine-stabilized estrone sulfate. Estrone, and estropipate are used to treat abnormalities related to gonadotropin hormone dysfunction, vasomotor symptoms, atrophic vaginitis, and vulvar atrophy associated with menopause, and for the prevention of osteoporosis due to estrogen deficiency.
Mechanism of actionEstrogens enter the cells of responsive tissues (e.g. female organs, breasts, hypothalamus, pituitary) where they interact with estrogen receptors. Hormone-bound estrogen receptors dimerize, translocate to the nucleus of cells and bind to estrogen response elements (ERE) of genes. Binding to ERE alters the transcription rate of affected genes. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) release from the anterior pituitary.
TargetKindPharmacological actionActionsOrganismUniProt ID
Estrogen receptorProteinyes
agonist
HumanP03372 details
Related Articles
Absorption43%
Volume of distributionNot Available
Protein binding> 95%
Metabolism

Hepatic.

SubstrateEnzymesProduct
Estrone
2-hydroxyestroneDetails
Estrone
4-hydroxyestroneDetails
Estrone
Not Available
Estrone sulfateDetails
Estrone
Not Available
Estrone glucuronideDetails
Estrone
Not Available
2-Hydroxyestrone sulfateDetails
Estrone
Not Available
4-Hydroxyestrone sulfateDetails
Route of eliminationNot Available
Half life19 hours
ClearanceNot Available
ToxicitySymptoms of overdose include nausea and vomiting. Estrogen related side effects include nausea, breast tenderness, fluid retention and edema, headaches and/or migraines, chloasma and poor contact lens fit. Estrogen hormone deficiency is associated with breakthrough bleeding, hypomenorrhea, irritability, depression and menopausal symptoms. Withdrawal bleeds may occur in females.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
17-Beta Hydroxysteroid Dehydrogenase III DeficiencyDiseaseSMP00356
Androgen and Estrogen MetabolismMetabolicSMP00068
Sulfate/Sulfite MetabolismMetabolicSMP00041
Sulfite oxidase deficiencyDiseaseSMP00532
Aromatase deficiencyDiseaseSMP00565
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Estrone is combined with 1,10-Phenanthroline.Experimental
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Estrone.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Estrone.Experimental, Illicit
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be increased when it is combined with Estrone.Experimental, Illicit
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Estrone.Experimental, Illicit
AbciximabEstrone may decrease the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Estrone can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Estrone.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Estrone.Approved
AcenocoumarolEstrone may decrease the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Estrone.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Estrone.Investigational
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Estrone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Estrone.Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Estrone.Approved
AlbendazoleThe serum concentration of Estrone can be increased when it is combined with Albendazole.Approved, Vet Approved
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Estrone.Approved
AldesleukinEstrone may decrease the antineoplastic activities of Aldesleukin.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Estrone.Experimental
AlectinibThe serum concentration of Estrone can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Estrone can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Estrone.Approved, Investigational
ALT-110The risk or severity of adverse effects can be increased when Estrone is combined with ALT-110.Investigational
Aluminum hydroxideThe bioavailability of Estrone can be decreased when combined with Aluminum hydroxide.Approved
Aluminum phosphateThe bioavailability of Estrone can be decreased when combined with Aluminum phosphate.Approved
AmantadineThe serum concentration of Estrone can be increased when it is combined with Amantadine.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Estrone is combined with Ambenonium.Approved
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Estrone.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be increased when it is combined with Estrone.Experimental
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Estrone.Approved
Aminohippuric acidThe serum concentration of Estrone can be increased when it is combined with Aminohippuric acid.Approved
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Estrone.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Estrone.Approved
AmiodaroneThe metabolism of Estrone can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Estrone.Approved
AmlodipineThe serum concentration of Estrone can be increased when it is combined with Amlodipine.Approved
Amphotericin BEstrone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Estrone can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Estrone can be increased when it is combined with Amsacrine.Approved
AnastrozoleThe therapeutic efficacy of Anastrozole can be decreased when used in combination with Estrone.Approved, Investigational
AncrodEstrone may decrease the anticoagulant activities of Ancrod.Investigational
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Estrone.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Estrone.Investigational
Anthrax immune globulin humanEstrone may increase the thrombogenic activities of Anthrax immune globulin human.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Estrone.Approved
Antithrombin III humanEstrone may decrease the anticoagulant activities of Antithrombin III human.Approved
ApixabanEstrone may decrease the anticoagulant activities of Apixaban.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Estrone.Approved, Investigational
AprepitantThe serum concentration of Estrone can be increased when it is combined with Aprepitant.Approved, Investigational
ArdeparinEstrone may decrease the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanEstrone may decrease the anticoagulant activities of Argatroban.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Estrone.Approved, Investigational
AstemizoleThe serum concentration of Estrone can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Estrone can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Estrone.Approved
AtomoxetineThe metabolism of Estrone can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Estrone can be increased when it is combined with Atorvastatin.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Estrone.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Estrone.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Estrone.Withdrawn
AzelastineThe serum concentration of Estrone can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Estrone can be increased when it is combined with Azithromycin.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Estrone.Approved, Investigational
BazedoxifeneThe serum concentration of Estrone can be increased when it is combined with Bazedoxifene.Approved, Investigational
BecaplerminEstrone may decrease the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe serum concentration of Beclomethasone can be increased when it is combined with Estrone.Investigational
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Estrone.Approved, Investigational
BendroflumethiazideEstrone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Estrone.Withdrawn
BenzocaineThe serum concentration of Estrone can be increased when it is combined with Benzocaine.Approved
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Estrone.Approved
BepridilThe serum concentration of Estrone can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Estrone.Approved, Vet Approved
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Estrone.Approved, Vet Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Estrone.Investigational
BexaroteneThe serum concentration of Estrone can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Estrone can be increased when it is combined with Biperiden.Approved
Bismuth SubcitrateThe bioavailability of Estrone can be decreased when combined with Bismuth Subcitrate.Approved
BivalirudinEstrone may decrease the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Estrone can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Estrone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Estrone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Estrone.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Estrone.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Estrone.Approved
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Estrone.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Estrone.Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Estrone.Approved
BumetanideEstrone may increase the hypokalemic activities of Bumetanide.Approved
BuprenorphineThe serum concentration of Estrone can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Estrone can be increased when it is combined with Buspirone.Approved, Investigational
C1 Esterase Inhibitor (Human)Estrone may increase the thrombogenic activities of C1 Esterase Inhibitor (Human).Approved
C1 Esterase Inhibitor (Recombinant)Estrone may increase the thrombogenic activities of C1 Esterase Inhibitor (Recombinant).Approved
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Estrone.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Estrone.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Estrone.Approved, Nutraceutical
Calcium carbonateThe bioavailability of Estrone can be decreased when combined with Calcium carbonate.Approved
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Estrone.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Estrone.Approved
CandesartanThe serum concentration of Estrone can be increased when it is combined with Candesartan.Approved
CapecitabineThe metabolism of Estrone can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Estrone can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Estrone can be increased when combined with Carbamazepine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Estrone.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Estrone.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Estrone can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Estrone can be increased when it is combined with Caspofungin.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Estrone.Experimental
CDX-110The risk or severity of adverse effects can be increased when Estrone is combined with CDX-110.Investigational
CelecoxibCelecoxib may increase the thrombogenic activities of Estrone.Approved, Investigational
CeritinibThe serum concentration of Estrone can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Estrone.Withdrawn
CertoparinEstrone may decrease the anticoagulant activities of Certoparin.Approved
Chenodeoxycholic acidThe therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Estrone.Approved
ChloroquineThe serum concentration of Estrone can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideEstrone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Estrone can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Estrone.Approved, Vet Approved
ChlorpropamideThe serum concentration of Estrone can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Estrone can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneEstrone may increase the hypokalemic activities of Chlorthalidone.Approved
CholecalciferolThe metabolism of Estrone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Estrone can be increased when it is combined with Cholesterol.Experimental
CholestyramineCholestyramine can cause a decrease in the absorption of Estrone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cholic AcidThe serum concentration of Estrone can be decreased when it is combined with Cholic Acid.Approved
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Estrone.Approved, Investigational
CilazaprilThe serum concentration of Estrone can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Estrone can be decreased when it is combined with Cimetidine.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Ciprofloxacin.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Estrone.Approved
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Estrone.Approved
Citric AcidEstrone may decrease the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Estrone can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Estrone can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Estrone.Approved, Illicit
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Estrone.Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Estrone.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Estrone.Approved
ClofazimineThe serum concentration of Estrone can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Estrone.Approved, Investigational
ClomipramineThe serum concentration of Estrone can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Estrone.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Estrone.Approved
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Estrone.Approved, Nutraceutical
ClotrimazoleThe metabolism of Estrone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Estrone.Approved
CobicistatThe metabolism of Estrone can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Estrone.Approved
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Estrone.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Estrone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Estrone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColforsinThe serum concentration of Estrone can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Estrone can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Estrone can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Estrone.Approved
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Estrone.Approved
CoumaphosThe risk or severity of adverse effects can be increased when Estrone is combined with Coumaphos.Vet Approved
CrizotinibThe metabolism of Estrone can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Estrone.Investigational
CyclophosphamideThe serum concentration of Estrone can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Estrone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Estrone can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Estrone.Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Estrone.Approved
DabrafenibThe serum concentration of Estrone can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Estrone can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Estrone.Approved
DalteparinEstrone may decrease the anticoagulant activities of Dalteparin.Approved
DanaparoidEstrone may decrease the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Estrone.Approved
DarunavirThe metabolism of Estrone can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Estrone can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Estrone can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Estrone.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Estrone is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Estrone can be decreased when it is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Estrone.Investigational
DelavirdineThe metabolism of Estrone can be decreased when combined with Delavirdine.Approved
DemecariumThe risk or severity of adverse effects can be increased when Estrone is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Estrone.Investigational
DesipramineThe serum concentration of Estrone can be increased when it is combined with Desipramine.Approved
DesirudinEstrone may decrease the anticoagulant activities of Desirudin.Approved
DesloratadineThe serum concentration of Estrone can be increased when it is combined with Desloratadine.Approved, Investigational
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Estrone.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Estrone.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Estrone.Experimental, Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Estrone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Estrone.Vet Approved
DextranEstrone may decrease the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Estrone may decrease the anticoagulant activities of Dextran 40.Approved
Dextran 70Estrone may decrease the anticoagulant activities of Dextran 70.Approved
Dextran 75Estrone may decrease the anticoagulant activities of Dextran 75.Approved
DextromethorphanThe serum concentration of Estrone can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Estrone.Approved, Illicit, Vet Approved
DichlorvosThe risk or severity of adverse effects can be increased when Estrone is combined with Dichlorvos.Vet Approved
DiclofenacThe serum concentration of Estrone can be increased when it is combined with Diclofenac.Approved, Vet Approved
DicoumarolEstrone may decrease the anticoagulant activities of Dicoumarol.Approved
DienestrolThe serum concentration of Estrone can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Estrone can be increased when it is combined with Diethylstilbestrol.Approved
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Estrone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Estrone.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Estrone.Approved
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Estrone.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Estrone.Approved
DigoxinThe serum concentration of Estrone can be decreased when it is combined with Digoxin.Approved
DihydroergotamineThe metabolism of Estrone can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Estrone.Illicit
DiltiazemThe metabolism of Estrone can be decreased when combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Estrone.Approved
DisulfiramThe metabolism of Estrone can be decreased when combined with Disulfiram.Approved
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Estrone.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Estrone.Approved, Investigational, Vet Approved
DonepezilThe risk or severity of adverse effects can be increased when Estrone is combined with Donepezil.Approved
DoxazosinThe serum concentration of Estrone can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Estrone can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Estrone.Approved, Investigational
DoxycyclineThe metabolism of Estrone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Estrone can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Estrone can be decreased when combined with Dronedarone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Estrone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Estrone.Investigational
DyphyllineThe serum concentration of Dyphylline can be increased when it is combined with Estrone.Approved
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Estrone.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Estrone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Estrone is combined with Echothiophate.Approved
Edetic AcidEstrone may decrease the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanEstrone may decrease the anticoagulant activities of Edoxaban.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Estrone is combined with Edrophonium.Approved
EfavirenzThe serum concentration of Estrone can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Estrone can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Estrone.Approved, Investigational
EnalaprilThe serum concentration of Estrone can be increased when it is combined with Enalapril.Approved, Vet Approved
EnoxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Enoxacin.Approved
EnoxaparinEstrone may decrease the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Estrone can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Estrone.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Estrone.Approved
EquileninThe serum concentration of Equilenin can be increased when it is combined with Estrone.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Estrone.Approved
ErgonovineThe serum concentration of Estrone can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Estrone can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Estrone.Approved, Investigational
ErythromycinThe metabolism of Estrone can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Estrone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Estrone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estrone can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Estrone can be increased when it is combined with Estriol.Approved, Vet Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Estrone.Approved
Etacrynic acidEstrone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Estrone.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Estrone can be increased when it is combined with Ethinyl Estradiol.Approved
Ethyl biscoumacetateEstrone may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the thrombogenic activities of Estrone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Estrone.Approved
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Estrone.Approved
EtoricoxibEtoricoxib may increase the thrombogenic activities of Estrone.Approved, Investigational
EtravirineThe serum concentration of Estrone can be decreased when it is combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Estrone.Approved
ExemestaneThe therapeutic efficacy of Exemestane can be decreased when used in combination with Estrone.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Estrone.Investigational
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Estrone.Approved
FelodipineThe serum concentration of Estrone can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Estrone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Estrone.Approved
FentanylThe serum concentration of Estrone can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe risk or severity of adverse effects can be increased when Estrone is combined with Fenthion.Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Estrone.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Estrone.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Estrone.Approved
FleroxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Estrone.Approved, Withdrawn
FloxuridineThe metabolism of Estrone can be decreased when combined with Floxuridine.Approved
fluasteroneThe serum concentration of fluasterone can be increased when it is combined with Estrone.Investigational
FluconazoleThe metabolism of Estrone can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Estrone.Approved
FluindioneEstrone may decrease the anticoagulant activities of Fluindione.Investigational
FlumequineThe risk or severity of adverse effects can be increased when Estrone is combined with Flumequine.Withdrawn
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Estrone.Approved, Vet Approved
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Estrone.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Estrone.Vet Approved
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Estrone.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Estrone.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Estrone.Approved, Withdrawn
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Estrone.Approved
FluorouracilThe metabolism of Estrone can be decreased when combined with Fluorouracil.Approved
FluoxetineThe serum concentration of Estrone can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluoxymesteroneEstrone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlupentixolThe serum concentration of Estrone can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Estrone can be increased when it is combined with Fluphenazine.Approved
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Estrone.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Estrone.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Estrone.Approved
FlurazepamThe serum concentration of Estrone can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Estrone.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Estrone.Approved
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Estrone.Approved
FluvastatinThe metabolism of Estrone can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Estrone can be decreased when combined with Fluvoxamine.Approved, Investigational
FondaparinuxEstrone may decrease the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumEstrone may decrease the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FormestaneThe serum concentration of Formestane can be increased when it is combined with Estrone.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Estrone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Estrone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Estrone can be increased when combined with Fosphenytoin.Approved
FurosemideEstrone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Estrone can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Estrone is combined with G17DT.Investigational
GabexateEstrone may decrease the anticoagulant activities of Gabexate.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Estrone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Estrone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Gatifloxacin.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Estrone.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Estrone.Approved
GemfibrozilThe metabolism of Estrone can be decreased when combined with Gemfibrozil.Approved
GemifloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Estrone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Estrone is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Estrone is combined with Ginkgo biloba.Approved, Nutraceutical
GlyburideThe serum concentration of Estrone can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Estrone can be increased when it is combined with Glycerol.Experimental
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Estrone.Approved
Gramicidin DThe serum concentration of Estrone can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Estrone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Grepafloxacin.Withdrawn
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Estrone.Approved
HE3286The serum concentration of HE3286 can be increased when it is combined with Estrone.Investigational
HeparinEstrone may decrease the anticoagulant activities of Heparin.Approved, Investigational
HexestrolThe serum concentration of Estrone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Estrone.Investigational
HirulogEstrone may decrease the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Estrone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Estrone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Estrone.Approved, Investigational
HydrochlorothiazideEstrone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Estrone.Approved, Vet Approved
HydroflumethiazideEstrone may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Estrone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Estrone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Estrone.Approved
IdelalisibThe serum concentration of Estrone can be increased when it is combined with Idelalisib.Approved
idraparinuxEstrone may decrease the anticoagulant activities of idraparinux.Investigational
ImatinibThe metabolism of Estrone can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Estrone.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Estrone.Approved
IndapamideEstrone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe metabolism of Estrone can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Estrone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Estrone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Estrone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Estrone is combined with INGN 225.Investigational
IrbesartanThe metabolism of Estrone can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Estrone.Approved, Investigational
IsavuconazoniumThe metabolism of Estrone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Estrone is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Estrone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Estrone.Withdrawn
IsradipineThe metabolism of Estrone can be decreased when combined with Isradipine.Approved
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Estrone.Investigational
ItraconazoleThe metabolism of Estrone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Estrone can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Estrone.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Estrone.Experimental
KetamineThe serum concentration of Estrone can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Estrone.Approved
KetoconazoleThe metabolism of Estrone can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Estrone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Estrone.Approved
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Estrone.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Estrone.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Estrone.Approved, Investigational
LapatinibThe serum concentration of Estrone can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Estrone.Approved
LeflunomideThe metabolism of Estrone can be decreased when combined with Leflunomide.Approved, Investigational
LenalidomideEstrone may increase the thrombogenic activities of Lenalidomide.Approved
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Estrone.Approved
LepirudinEstrone may decrease the anticoagulant activities of Lepirudin.Approved
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Estrone.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Levofloxacin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Estrone.Approved
LevothyroxineThe serum concentration of Estrone can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Estrone can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Estrone.Approved
LiothyronineThe serum concentration of Estrone can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Estrone can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Estrone can be increased when it is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Estrone.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Lomefloxacin.Approved
LomitapideThe serum concentration of Estrone can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Estrone.Approved
LopinavirThe metabolism of Estrone can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Estrone can be increased when it is combined with Loratadine.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Estrone.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Estrone.Approved
LovastatinThe metabolism of Estrone can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Estrone.Approved
LuliconazoleThe serum concentration of Estrone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Estrone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may increase the thrombogenic activities of Estrone.Approved, Investigational
MagaldrateThe bioavailability of Estrone can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of Estrone can be decreased when combined with Magnesium carbonate.Approved
Magnesium hydroxideThe bioavailability of Estrone can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of Estrone can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Estrone.Approved
Magnesium TrisilicateThe bioavailability of Estrone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Estrone is combined with Malathion.Approved, Investigational
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Estrone.Approved, Investigational
MaprotilineThe serum concentration of Estrone can be increased when it is combined with Maprotiline.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Estrone.Approved
ME-609The serum concentration of ME-609 can be increased when it is combined with Estrone.Investigational
MebendazoleThe serum concentration of Estrone can be increased when it is combined with Mebendazole.Approved, Vet Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Estrone.Approved, Vet Approved
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Estrone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Estrone.Approved
MefloquineThe serum concentration of Estrone can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Estrone can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Estrone.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Estrone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Estrone is combined with Memantine.Approved, Investigational
MeprobamateThe serum concentration of Estrone can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Estrone.Approved
MestranolThe serum concentration of Estrone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Estrone.Withdrawn
MethadoneThe serum concentration of Estrone can be increased when it is combined with Methadone.Approved
MethallenestrilThe serum concentration of Estrone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Estrone is combined with Methanesulfonyl Fluoride.Investigational
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Estrone.Approved
MethyclothiazideEstrone may increase the hypokalemic activities of Methyclothiazide.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Estrone.Approved, Vet Approved
MethyltestosteroneEstrone may increase the fluid retaining activities of Methyltestosterone.Approved
MetolazoneEstrone may increase the hypokalemic activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Estrone.Approved, Investigational
MexiletineThe metabolism of Estrone can be decreased when combined with Mexiletine.Approved
MibefradilThe serum concentration of Estrone can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Estrone can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Estrone can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe therapeutic efficacy of Estrone can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Estrone is combined with Minaprine.Approved
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Estrone.Approved
MitomycinThe serum concentration of Estrone can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Estrone can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Estrone can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MivacuriumMivacurium may increase the adverse neuromuscular activities of Estrone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Estrone.Investigational
ModafinilThe serum concentration of Estrone can be decreased when it is combined with Modafinil.Approved, Investigational
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Estrone.Approved, Vet Approved
MorphineThe serum concentration of Morphine can be decreased when it is combined with Estrone.Approved, Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Estrone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Estrone.Approved
NabumetoneNabumetone may increase the thrombogenic activities of Estrone.Approved
NadololThe serum concentration of Nadolol can be decreased when it is combined with Estrone.Approved
NadroparinEstrone may decrease the anticoagulant activities of Nadroparin.Approved
NafamostatEstrone may decrease the anticoagulant activities of Nafamostat.Investigational
NafcillinThe serum concentration of Estrone can be decreased when it is combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Estrone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Estrone is combined with Nalidixic Acid.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Estrone.Approved, Vet Approved
NaltrexoneThe serum concentration of Estrone can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Estrone.Approved, Vet Approved
NaringeninThe serum concentration of Estrone can be increased when it is combined with Naringenin.Experimental
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Estrone.Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Estrone.Investigational
NefazodoneThe metabolism of Estrone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Estrone can be decreased when combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Nemonoxacin.Investigational
NeostigmineThe serum concentration of Estrone can be increased when it is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Estrone.Approved
NetupitantThe serum concentration of Estrone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Estrone can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Estrone can be decreased when combined with Nicardipine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Estrone is combined with Nicorandil.Approved
NicotineThe metabolism of Estrone can be decreased when combined with Nicotine.Approved
NifedipineThe serum concentration of Estrone can be decreased when it is combined with Nifedipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Estrone.Approved
NilotinibThe metabolism of Estrone can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Estrone.Approved, Withdrawn
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Estrone.Approved
NisoldipineThe serum concentration of Estrone can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Estrone can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Estrone can be increased when it is combined with Nitrendipine.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Estrone.Investigational
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Estrone.Approved
NorethisteroneThe serum concentration of Estrone can be decreased when it is combined with Norethisterone.Approved
NorfloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Ofloxacin.Approved
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Estrone.Approved, Investigational
OlaparibThe metabolism of Estrone can be decreased when combined with Olaparib.Approved
Oleoyl estroneThe serum concentration of Oleoyl estrone can be increased when it is combined with Estrone.Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Estrone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Estrone.Approved
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Estrone.Approved
OmeprazoleThe serum concentration of Estrone can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Estrone.Vet Approved
OsimertinibThe serum concentration of Estrone can be increased when it is combined with Osimertinib.Approved
OspemifeneThe risk or severity of adverse effects can be increased when Estrone is combined with Ospemifene.Approved
OtamixabanEstrone may decrease the anticoagulant activities of Otamixaban.Investigational
OxandroloneEstrone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Estrone.Approved
OxymetholoneEstrone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Estrone.Withdrawn
P-NitrophenolThe serum concentration of Estrone can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Estrone.Approved, Vet Approved
PalbociclibThe serum concentration of Estrone can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Estrone can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Estrone.Approved, Investigational
PantoprazoleThe serum concentration of Estrone can be increased when it is combined with Pantoprazole.Approved
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Estrone.Approved
ParecoxibParecoxib may increase the thrombogenic activities of Estrone.Approved
ParoxetineThe serum concentration of Estrone can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Estrone.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Pefloxacin.Approved
Peginterferon alfa-2bThe serum concentration of Estrone can be increased when it is combined with Peginterferon alfa-2b.Approved
PentobarbitalThe metabolism of Estrone can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateEstrone may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe serum concentration of Estrone can be increased when it is combined with Perindopril.Approved
PhenindioneEstrone may decrease the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Estrone can be increased when combined with Phenobarbital.Approved
PhenprocoumonEstrone may decrease the anticoagulant activities of Phenprocoumon.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Estrone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Estrone.Approved, Vet Approved
PhenytoinThe metabolism of Estrone can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Estrone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Estrone.Approved, Investigational
PimozideThe serum concentration of Estrone can be increased when it is combined with Pimozide.Approved
PiretanideEstrone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Estrone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Estrone.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Estrone.Approved
Platelet Activating FactorThe serum concentration of Estrone can be decreased when it is combined with Platelet Activating Factor.Experimental
Polyestradiol phosphateThe serum concentration of Estrone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideEstrone may increase the hypokalemic activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Estrone.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Estrone.Approved
PosaconazoleThe metabolism of Estrone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Estrone.Approved, Nutraceutical
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Estrone.Approved
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Estrone.Approved
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Estrone.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Estrone.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Estrone.Approved, Vet Approved
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Estrone.Experimental
PrimidoneThe metabolism of Estrone can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Estrone can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Estrone can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromestrieneThe serum concentration of Estrone can be increased when it is combined with Promestriene.Investigational
PromethazineThe serum concentration of Estrone can be increased when it is combined with Promethazine.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Estrone.Approved
PropafenoneThe serum concentration of Estrone can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Estrone.Approved, Investigational
Protein CEstrone may decrease the anticoagulant activities of Protein C.Approved
Protein S humanEstrone may decrease the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeEstrone may decrease the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe serum concentration of Estrone can be increased when it is combined with Protriptyline.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Estrone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Estrone is combined with Pyridostigmine.Approved
PyrimethamineThe metabolism of Estrone can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Estrone can be increased when it is combined with Quazepam.Approved, Illicit
QuercetinThe serum concentration of Estrone can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Estrone.Approved
QuinacrineThe serum concentration of Estrone can be increased when it is combined with Quinacrine.Approved
QuinestrolThe serum concentration of Estrone can be increased when it is combined with Quinestrol.Approved
QuinethazoneEstrone may increase the hypokalemic activities of Quinethazone.Approved
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Estrone.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Estrone.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Estrone is combined with Rabies vaccine.Approved
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Estrone.Approved
RanolazineThe serum concentration of Estrone can be increased when it is combined with Ranolazine.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Estrone.Withdrawn
ReboxetineThe serum concentration of Estrone can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Estrone can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Estrone can be decreased when it is combined with Reserpine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Estrone.Experimental, Investigational
ReviparinEstrone may decrease the anticoagulant activities of Reviparin.Approved
RifabutinThe metabolism of Estrone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Estrone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Estrone can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Estrone can be increased when it is combined with Rilpivirine.Approved
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Estrone.Approved
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Estrone.Approved, Investigational
RitonavirThe metabolism of Estrone can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanEstrone may decrease the anticoagulant activities of Rivaroxaban.Approved
RivastigmineThe risk or severity of adverse effects can be increased when Estrone is combined with Rivastigmine.Approved, Investigational
RofecoxibRofecoxib may increase the thrombogenic activities of Estrone.Investigational, Withdrawn
RolapitantThe serum concentration of Estrone can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Estrone.Approved, Investigational
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Estrone.Approved, Investigational
RosoxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Rosoxacin.Approved
S EquolThe serum concentration of Estrone can be increased when it is combined with S Equol.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Estrone.Approved
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Estrone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Estrone.Approved
SaquinavirThe metabolism of Estrone can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Estrone can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Estrone can be increased when combined with Secobarbital.Approved, Vet Approved
SecoisolariciresinolThe serum concentration of Estrone can be increased when it is combined with Secoisolariciresinol.Investigational
SelegilineThe serum concentration of Estrone can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Estrone.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Estrone.Approved, Investigational
SertralineThe serum concentration of Estrone can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Estrone can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Estrone.Approved
SiltuximabThe serum concentration of Estrone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Estrone can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Estrone can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Estrone can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Estrone.Approved, Investigational
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Estrone.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Estrone.Approved
Somatropin recombinantThe therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Estrone.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Estrone.Approved, Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Sparfloxacin.Approved
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Estrone.Experimental
SpironolactoneThe serum concentration of Estrone can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Estrone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Estrone.Investigational
St. John's WortThe serum concentration of Estrone can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololEstrone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StaurosporineThe serum concentration of Estrone can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Estrone can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Estrone can be decreased when it is combined with Streptozocin.Approved
SulfadiazineThe metabolism of Estrone can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Estrone can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Estrone.Approved
SulfinpyrazoneThe serum concentration of Estrone can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Estrone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Estrone.Approved
SulodexideEstrone may decrease the anticoagulant activities of Sulodexide.Approved, Investigational
SumatriptanThe serum concentration of Estrone can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Estrone can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Estrone.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Estrone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Estrone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe serum concentration of Estrone can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Estrone can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Estrone can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Estrone.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Estrone.Approved
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Estrone.Approved
TelithromycinThe metabolism of Estrone can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Estrone can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Temafloxacin.Withdrawn
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Estrone.Approved
TenofovirThe metabolism of Estrone can be decreased when combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Estrone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Estrone.Vet Approved
TerazosinThe serum concentration of Estrone can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Estrone can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Estrone can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Estrone can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Estrone can be increased when it is combined with Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Estrone is combined with TG4010.Investigational
ThalidomideEstrone may increase the thrombogenic activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Estrone can be decreased when combined with Theophylline.Approved
ThiotepaThe metabolism of Estrone can be decreased when combined with Thiotepa.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Estrone.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Estrone.Approved
TiboloneThe serum concentration of Estrone can be increased when it is combined with Tibolone.Approved
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Estrone.Approved
TiclopidineThe metabolism of Estrone can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be decreased when it is combined with Estrone.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Estrone.Investigational
TipranavirEstrone may increase the dermatologic adverse activities of Tipranavir.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Estrone.Approved
TocilizumabThe serum concentration of Estrone can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Estrone can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Estrone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Estrone.Approved
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Estrone.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Estrone.Approved, Investigational
TorasemideEstrone may increase the hypokalemic activities of Torasemide.Approved
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Estrone.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Estrone.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Estrone.Approved
TrazodoneThe serum concentration of Estrone can be decreased when it is combined with Trazodone.Approved, Investigational
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Estrone.Approved, Vet Approved
TrichlorfonThe risk or severity of adverse effects can be increased when Estrone is combined with Trichlorfon.Vet Approved
TrichlormethiazideEstrone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Estrone can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Estrone can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Estrone can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Estrone can be increased when it is combined with Trimipramine.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Estrone.Approved
TroleandomycinThe serum concentration of Estrone can be increased when it is combined with Troleandomycin.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Estrone is combined with Tubocurarine.Approved
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Estrone.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Estrone.Approved
Ursodeoxycholic acidThe therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Estrone.Approved, Investigational
ValdecoxibValdecoxib may increase the thrombogenic activities of Estrone.Investigational, Withdrawn
Valproic AcidThe metabolism of Estrone can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Estrone can be decreased when combined with Valsartan.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Estrone.Approved
VemurafenibThe serum concentration of Estrone can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Estrone.Approved
VenlafaxineThe metabolism of Estrone can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Estrone can be decreased when combined with Verapamil.Approved
VinblastineThe serum concentration of Estrone can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Estrone.Approved, Investigational
VinorelbineThe serum concentration of Estrone can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Estrone.Approved
Vitamin CThe serum concentration of Estrone can be increased when it is combined with Vitamin C.Approved, Nutraceutical
VoriconazoleThe metabolism of Estrone can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinEstrone may increase the anticoagulant activities of Warfarin.Approved
XimelagatranEstrone may decrease the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Estrone may decrease the anticoagulant activities of Ym150.Investigational
ZafirlukastThe metabolism of Estrone can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Estrone.Approved
ZeranolThe serum concentration of Estrone can be increased when it is combined with Zeranol.Vet Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Estrone.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Estrone.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Estrone can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Estrone can be decreased when combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Estrone.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Seiichi Takano, Kunio Ogasawara, “Method for producing (+)-estrone derivatives.” U.S. Patent US5424462, issued January, 1965.

US5424462
General References
  1. Miyoshi Y, Tanji Y, Taguchi T, Tamaki Y, Noguchi S: Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women. Clin Cancer Res. 2003 Jun;9(6):2229-33. [PubMed:12796390 ]
  2. Kajta M, Lason W, Bien E, Marszal M: Neuroprotective effects of estrone on NMDA-induced toxicity in primary cultures of rat cortical neurons are independent of estrogen receptors. Pol J Pharmacol. 2002 Nov-Dec;54(6):727-9. [PubMed:12866733 ]
External Links
ATC CodesG03CA07G03CC04
AHFS Codes
  • 68:16.04
  • 92:02.00*
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (76.2 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9529
Caco-2 permeable+0.8934
P-glycoprotein substrateSubstrate0.6001
P-glycoprotein inhibitor INon-inhibitor0.9066
P-glycoprotein inhibitor IINon-inhibitor0.8882
Renal organic cation transporterNon-inhibitor0.73
CYP450 2C9 substrateNon-substrate0.6624
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.729
CYP450 1A2 substrateInhibitor0.9017
CYP450 2C9 inhibitorNon-inhibitor0.9353
CYP450 2D6 inhibitorNon-inhibitor0.9599
CYP450 2C19 inhibitorNon-inhibitor0.8954
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8681
Ames testNon AMES toxic0.9268
CarcinogenicityNon-carcinogens0.8917
BiodegradationNot ready biodegradable0.9717
Rat acute toxicity1.9267 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8711
hERG inhibition (predictor II)Inhibitor0.5459
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Wyeth ayerst laboratories
  • Watson laboratories inc
  • Parkedale pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
CreamVaginal0.1 %
SuppositoryVaginal.25 mg
CreamVaginal1 mg
Prices
Unit descriptionCostUnit
Estrone powder21.42USD g
Estrone crystal11.76USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point260.2 °CPhysProp
boiling point154 °CPhysProp
water solubility30 mg/L (at 25 °C)MERCK INDEX (1996)
logP3.13HANSCH,C ET AL. (1995)
logS-3.96ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00394 mg/mLALOGPS
logP4.03ALOGPS
logP4.31ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)10.33ChemAxon
pKa (Strongest Basic)-5.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity79.08 m3·mol-1ChemAxon
Polarizability31.27 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.95 KB)
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-MS (1 TMS)splash10-05ox-3951000000-8bc438f505b3cf49b21fView in MoNA
GC-MSGC-MS Spectrum - GC-MS (1 MEOX; 1 TMS)splash10-003u-4942000000-a72ea34d85d9d524c247View in MoNA
GC-MSGC-MS Spectrum - GC-MS (1 MEOX; 1 TMS)splash10-0019-8931000000-aad9803af812c7c40f53View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-00di-0190000000-071e67516e11357ff64eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-0a4j-4910000000-20e059a7c508ba492af3View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-067i-9700000000-9ff5214f08822f238fa9View in MoNA
LC-MS/MSLC-MS/MS Spectrum - EI-B (HITACHI M-80) , Positivesplash10-00di-2940000000-3b9744c27d6a3d2eff6eView in MoNA
MSMass Spectrum (Electron Ionization)splash10-00di-2930000000-c99df908474247066a2bView in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassEstrane steroids
Direct ParentEstrogens and derivatives
Alternative Parents
Substituents
  • Estrogen-skeleton
  • Oxosteroid
  • 17-oxosteroid
  • Hydroxysteroid
  • 3-hydroxysteroid
  • Phenanthrene
  • Tetralin
  • Benzenoid
  • Ketone
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription fact...
Gene Name:
ESR1
Uniprot ID:
P03372
Molecular Weight:
66215.45 Da
References
  1. Margeat E, Bourdoncle A, Margueron R, Poujol N, Cavailles V, Royer C: Ligands differentially modulate the protein interactions of the human estrogen receptors alpha and beta. J Mol Biol. 2003 Feb 7;326(1):77-92. [PubMed:12547192 ]
  2. Sasson S: Equilibrium binding analysis of estrogen agonists and antagonists: relation to the activation of the estrogen receptor. Pathol Biol (Paris). 1991 Jan;39(1):59-69. [PubMed:2011412 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Lin Y, Lu P, Tang C, Mei Q, Sandig G, Rodrigues AD, Rushmore TH, Shou M: Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos. 2001 Apr;29(4 Pt 1):368-74. [PubMed:11259318 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT: Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98. [PubMed:12865317 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Leukotriene-b4 20-monooxygenase activity
Specific Function:
Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity toward prostaglandins A1 and E1. Oxidizes arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE).
Gene Name:
CYP4A11
Uniprot ID:
Q02928
Molecular Weight:
59347.31 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Tan E, Lu T, Pang KS: Futile cycling of estrone sulfate and estrone in the recirculating perfused rat liver preparation. J Pharmacol Exp Ther. 2001 Apr;297(1):423-36. [PubMed:11259571 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name:
SLCO2B1
Uniprot ID:
O94956
Molecular Weight:
76709.98 Da
References
  1. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A: Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res. 2001 Sep;18(9):1262-9. [PubMed:11683238 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y: Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009 Sep;100(9):1701-7. doi: 10.1111/j.1349-7006.2009.01213.x. Epub 2009 May 12. [PubMed:19493273 ]
  2. Kim WY, Benet LZ: P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93. [PubMed:15290871 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Kanai N, Lu R, Bao Y, Wolkoff AW, Vore M, Schuster VL: Estradiol 17 beta-D-glucuronide is a high-affinity substrate for oatp organic anion transporter. Am J Physiol. 1996 Feb;270(2 Pt 2):F326-31. [PubMed:8779894 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Imai Y, Tsukahara S, Asada S, Sugimoto Y: Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res. 2004 Jun 15;64(12):4346-52. [PubMed:15205350 ]
  2. Sugimoto Y, Tsukahara S, Imai Y, Sugimoto Y, Ueda K, Tsuruo T: Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol Cancer Ther. 2003 Jan;2(1):105-12. [PubMed:12533678 ]
  3. Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y: ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem. 2003 Jun 20;278(25):22644-9. Epub 2003 Apr 7. [PubMed:12682043 ]
  4. Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y: Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol. 2003 Sep;64(3):610-8. [PubMed:12920197 ]
  5. Miwa M, Tsukahara S, Ishikawa E, Asada S, Imai Y, Sugimoto Y: Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants. Int J Cancer. 2003 Dec 10;107(5):757-63. [PubMed:14566825 ]
  6. Imai Y, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y: Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance. Jpn J Cancer Res. 2002 Mar;93(3):231-5. [PubMed:11927002 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A: Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res. 2001 Sep;18(9):1262-9. [PubMed:11683238 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23